Ospedale Santa Maria Annunziata
- Address
- lock Available on a paid plan
Immune System Diseases
The research team at Ospedale Santa Maria Annunziata investigates disorders of the immune system, notably IgA nephropathy and chronic kidney injury, seeking therapies that lower protein loss and preserve renal function.
- Early corticosteroid treatment after kidney biopsy
- SGLT2 inhibitor combined with renin‑angiotensin blockade
- Non‑inferiority of glucose‑sparing dialysis solutions
These studies aim to improve patient outcomes while reducing treatment‑related side effects, positioning the site as a hub for innovative renal research in Europe.
Male Urogenital Diseases
Although current trials focus on other specialties, the department is equipped to conduct studies on male urogenital conditions, leveraging its multidisciplinary expertise and modern facilities.
- Evaluation of novel hormonal therapies
- Assessment of minimally invasive surgical techniques
- Quality‑of‑life measurements in urologic patients
The hospital’s commitment to expanding research in this therapeutic area promises future opportunities for patients and investigators alike.
Neoplasms
The oncology program concentrates on a range of cancers, including breast cancer, melanoma, and metastatic colorectal cancer, with trials designed to test targeted agents and combination regimens.
- PIK3CA‑mutated hormone‑positive breast cancer therapy
- First‑line FOLFIRI with cetuximab or bevacizumab in RAS/BRAF‑selected mCRC
- Neoadjuvant plus adjuvant vemurafenib, cobimetinib, and atezolizumab for high‑risk melanoma
These investigations seek to enhance survival and disease‑free intervals, offering patients access to cutting‑edge treatments within a leading European cancer center.
Virus Diseases
In the field of viral infections, the site conducts research on HIV‑1 management, focusing on regimen simplification and long‑term viral suppression.
- Early switch to a two‑drug dolutegravir/lamivudine regimen
- Virologic rebound monitoring using FDA snapshot criteria
- Patient‑reported outcomes on treatment tolerability
The goal is to maintain effective control of the virus while reducing pill burden and potential side effects, contributing valuable data to global HIV care strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 36 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale Santa Maria Annunziata
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Trial of Endocrine Therapy Versus Radiation Therapy in Women Aged ≥70 with Luminal A-like Early Stage Breast Cancer | University Of Florence | Phase III | Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 36 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 2 | Unknown | 2023-07-06 | 2023-08-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.